Aisling Capital Management
Latest statistics and disclosures from Aisling Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BBIO, VRNA, SNDX, BMEA, CMPS, and represent 92.27% of Aisling Capital Management's stock portfolio.
- Reduced shares in these 1 stock: SYRE.
- Sold out of its position in SYRE.
- Aisling Capital Management was a net seller of stock by $-829k.
- Aisling Capital Management has $335M in assets under management (AUM), dropping by 38.14%.
- Central Index Key (CIK): 0001766721
Tip: Access up to 7 years of quarterly data
Positions held by Aisling Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 16 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 73.1 | $245M | 6.1M | 40.37 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 6.6 | $22M | 1.1M | 19.88 |
|
|
| Syndax Pharmaceuticals (SNDX) | 6.6 | $22M | 1.0M | 21.61 |
|
|
| Biomea Fusion (BMEA) | 3.5 | $12M | 799k | 14.52 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 2.5 | $8.4M | 965k | 8.75 |
|
|
| Monte Rosa Therapeutics (GLUE) | 2.5 | $8.3M | 1.5M | 5.65 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 1.1 | $3.8M | 2.5M | 1.51 |
|
|
| Spruce Biosciences (SPRB) | 1.1 | $3.5M | 1.2M | 2.93 |
|
|
| Poseida Therapeutics I (PSTX) | 1.0 | $3.5M | 1.0M | 3.36 |
|
|
| Marker Therapeutics (MRKR) | 0.5 | $1.7M | 314k | 5.50 |
|
|
| Elevation Oncology (ELEV) | 0.5 | $1.5M | 2.8M | 0.54 |
|
|
| Reneo Pharmaceuticals (RPHM) | 0.4 | $1.4M | 886k | 1.60 |
|
|
| Avrobio Ord (AVRO) | 0.4 | $1.4M | 1.0M | 1.36 |
|
|
| Aclaris Therapeutics (ACRS) | 0.1 | $456k | 435k | 1.05 |
|
|
| Viracta Therapeutics (VIRX) | 0.0 | $165k | 289k | 0.57 |
|
|
| Atreca Cl A Com (BCEL) | 0.0 | $51k | 388k | 0.13 |
|
Past Filings by Aisling Capital Management
SEC 13F filings are viewable for Aisling Capital Management going back to 2018
- Aisling Capital Management 2023 Q4 filed Feb. 7, 2024
- Aisling Capital Management 2023 Q3 filed Nov. 13, 2023
- Aisling Capital Management 2023 Q2 filed Aug. 11, 2023
- Aisling Capital Management 2023 Q1 filed May 9, 2023
- Aisling Capital Management 2022 Q4 filed Feb. 9, 2023
- Aisling Capital Management 2022 Q3 filed Nov. 3, 2022
- Aisling Capital Management 2022 Q2 filed Aug. 10, 2022
- Aisling Capital Management 2022 Q1 filed May 10, 2022
- Aisling Capital Management 2021 Q4 filed Feb. 18, 2022
- Aisling Capital Management 2021 Q3 filed Nov. 12, 2021
- Aisling Capital Management 2021 Q2 filed Aug. 6, 2021
- Aisling Capital Management 2021 Q1 filed May 14, 2021
- Aisling Capital Management 2020 Q4 restated filed Feb. 5, 2021
- Aisling Capital Management 2020 Q4 filed Feb. 4, 2021
- Aisling Capital Management 2020 Q3 filed Nov. 12, 2020
- Aisling Capital Management 2020 Q2 filed Aug. 10, 2020